10-Q: DarioHealth Corp. Reports Q1 2025 Results: Revenue Up 17.3% Amid Strategic Refinancing and New Partnerships

Sentiment:

Quarterly Report 14 May 2025 6:06 AM

DarioHealth Corp. announces a 17.3% increase in revenue for Q1 2025, driven by commercial channel growth, alongside strategic debt refinancing and new partnerships aimed at expanding its B2B2C strategy.

Capital raiseThe company refinanced its existing debt facility with a new $32.5 million credit agreement and may draw an additional $17.5 million based on certain conditions.The company issued warrants to purchase 2,114,140 shares of its Common Stock, with an exercise price of $0.8278.Up to $2.5 million of the loaned amount can be converted into shares of the company's common stock at a price of $0.9933 per share.

Worse than expectedThe net loss increased by 28.6% to $9.227 million, indicating ongoing challenges with profitability.

Summary

DarioHealth Corp. reported a 17.3% increase in revenue for the three months ended March 31, 2025, reaching $6.752 million compared to $5.758 million in the same period of 2024.
The increase in revenue was primarily driven by growth in the commercial channel.
The company's gross profit increased to $3.882 million (57.5% of revenues) from $2.432 million (42.2% of revenues) in the prior year period.
Research and development expenses decreased by 38.2% to $4.108 million.
Sales and marketing expenses decreased by 15% to $5.873 million.
General and administrative expenses decreased by 50.9% to $3.310 million.
The company's net loss increased by 28.6% to $9.227 million.
As of March 31, 2025, DarioHealth had $27.854 million in cash and cash equivalents.
The company refinanced its existing debt facility with a new $32.5 million credit agreement and may draw an additional $17.5 million based on certain conditions.
DarioHealth signed 14 new clients year-to-date, including one national and one regional health plan and 12 employers.
The company announced new partnerships with a U.S. healthcare institution and a leading benefit plan administrator.
A new study was published demonstrating the effectiveness of personalized digital health interventions to drive flu vaccine awareness in Dario members living with diabetes.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue growth and strategic partnerships are positive, the increasing net loss and dependence on a major customer raise concerns. The debt refinancing provides flexibility but also adds financial risk.

Positives

Revenue increased by 17.3% year-over-year, indicating growth in the business.
Gross profit margin improved significantly, reflecting better cost management and revenue mix.
Operating expenses, including R&D, sales and marketing, and G&A, decreased, showing improved efficiency.
The company successfully refinanced its debt, providing additional operational flexibility.
New client acquisitions and partnerships demonstrate market traction and expansion opportunities.
Published research supports the effectiveness of DarioHealth's interventions.

Negatives

Net loss increased by 28.6% to $9.227 million, indicating ongoing challenges with profitability.
The company has an accumulated deficit of $404.409 million.
The company is dependent on a major customer for a significant portion of its revenue, creating customer concentration risk.
The company's auditor has expressed doubt about its ability to continue as a going concern.

Risks

The company's principal executive offices and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel, including the multi front war Israel is currently facing.
Significant changes or developments in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the reaction of other countries thereto, may have a material adverse effect on the company's business and financial statements.
The market price of the company's common stock has been extremely volatile and may continue to be volatile due to numerous circumstances beyond its control.
Nasdaq may delist the company's securities from trading on its exchange, which could limit investors ability to make transactions in its securities and subject the company to additional trading restrictions.

Future Outlook

Management believes that the proceeds from prior private placements and the Credit Facility, combined with cash on hand and short-term investments, are sufficient to meet obligations for at least twelve months. The company aims to add 40 new clients in 2025.

Management Comments

The company is committed to transforming healthcare by delivering a comprehensive and highly engaging whole-person health platform.
The company believes that most existing digital health solutions in the market fail to deliver improved health outcomes because users are not engaged due to a lack relevance, personalization, consumerization, and longitudinal data and information.
The company believes that its D2C marketplace roots and continued focus delivers better user experiences, longer sustained engagement, stronger clinical outcomes, at the most affordable prices, that then delivers the highest return on investment (ROI) in the industry.

Industry Context

The announcement reflects a broader trend in the digital health industry towards consolidation and the development of comprehensive, integrated platforms. The focus on B2B2C partnerships and GLP-1 support programs aligns with the growing demand for accessible and effective chronic condition management solutions.

Comparison to Industry Standards

DarioHealth's revenue growth of 17.3% is comparable to other digital health companies in the growth phase, such as Teladoc Health and Livongo (prior to its acquisition by Teladoc), which experienced similar growth rates in their early stages.
The gross profit margin of 57.5% is within the typical range for digital health companies, but there is room for improvement compared to industry leaders like Teladoc, which has historically maintained gross margins above 60%.
The company's focus on B2B2C partnerships is a common strategy in the digital health space, similar to companies like Omada Health and Accolade, which leverage partnerships with employers and health plans to reach a wider audience.
The integration of GLP-1 support programs aligns with the growing trend of digital health companies offering specialized solutions for specific conditions, as seen with companies like Virta Health and Calibrate, which focus on diabetes and metabolic health.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Financial Officer, Treasurer and Secretary	Zvi Ben David	Chen Franco-Yehuda	2025-05-15	Not specified

Related Party Transactions

The company appointed a new non-executive director to its Board who is a member of a consulting firm that has provided investment and business consulting services to the Company since 2021 under a consulting agreement.
The company agreed to pay the consultant a monthly cash retainer upon the successful completion of certain milestones and issued 150,000 restricted shares of common stock to the consulting firm, vesting quarterly over a four-year period.
The company entered into a second amendment to the consulting agreement, pursuant to which it agreed to pay the consulting firm a fixed monthly cash retainer of $10.

Stakeholder Impact

Shareholders: The stock price volatility and potential delisting from Nasdaq could negatively impact shareholder value.
Employees: Management changes and cost-cutting measures could affect employee morale and job security.
Customers: New partnerships and product offerings could enhance the value proposition for customers.
Creditors: The debt refinancing could impact the company's creditworthiness and ability to meet its obligations.

Next Steps

Continue to monitor the closing bid price for the Common Stock and consider various measures to resolve the deficiency and regain compliance with the minimum bid price requirement, including a stock split, if necessary.
Continue to scale up the commercial launch of products and meet commercial sales targets.
Obtain additional capital resources in the near term.

Key Dates

Date	Description
2023-05-01	Company refinanced its existing $25,000 credit facility with a new $30,000 credit facility with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P.
2024-02-15	Company acquired Twill, Inc.
2024-09-16	Company received a written notice from the Nasdaq Stock Market LLC (Nasdaq) indicating that it is not in compliance with Nasdaq Listing Rule 5550(a)(2), as its closing bid price for its common stock was below $1.00 per share for the last 30 consecutive business days.
2024-12-16	Company entered into securities purchase agreements (each, a Series D Purchase Agreement), pursuant to which it issued 7,055 and 11,750 Series D and D-1 preferred shares, respectively, at a purchase price of $1,000 per preferred share.
2025-01-07	Company entered into securities purchase agreements (each, a Series D Purchase Agreement) with accredited investors relating to an offering (the Series D Offering) and the sale of an aggregate of (i) 4,950 shares of newly designated Series D-2 Preferred Stock (the Series D-2 Preferred Stock), and (ii) 1,850 shares of Series D-3 Preferred Stock (the Series D-3 Preferred Stock), at a purchase price of $1,000 for each share of preferred stock.
2025-03-17	From the pre-funded warrants that were issued in July 2020, 360,298 were exercised on a cashless basis into 359,977 shares of Common Stock.
2025-03-18	Company received a letter from Nasdaq approving an extension of an additional 180 calendar days to regain compliance with the minimum bid price requirement, or until September 15, 2025.
2025-03-31	End of the quarterly period.
2025-04-08	Company announced a new employer partnership with one of the nation's most respected research and medical institutions.
2025-04-17	Company announced a new strategic partnership with a leading benefit administrator to deliver its comprehensive cardiometabolic solution including a GLP-1 support program and full AI-driven digital health suite to employers.
2025-04-28	Company held a special meeting of stockholders in which the stockholders approved the (A) the issuance of shares of its common stock, in excess of 20% of its issued and outstanding shares of Common Stock, upon: (i) the conversion of 25,605 shares of its Series D, D-1, D-2 and D-3 Preferred Stock into an aggregate of 33,956,850 shares of Common Stock, which were issued pursuant to private placement transactions that closed on December 18, 2024 and January 14, 2025 (the Private Placements), (ii) the issuance of up to 13,582,740 shares of Common Stock issuable as dividends to the Series D, D-1, D-2 and D-3 Preferred Stock; and (iii) the issuance of up to 4,175,070 shares of Common Stock issuable as share consideration provided under the Lock Up Agreements; and (B) (i) reduce the exercise price of certain warrants to purchase 584,882 shares of Common Stock issued to Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. (collectively Avenue) to $0.7208 per share, and (ii) to permit the conversion of up to two million dollars of the principal amount of the loan issued by Avenue to it at a conversion price of $0.8650 per share.
2025-04-30	Company refinanced its existing $30,000 credit facility with a new $32,500 credit agreement.
2025-05-01	Company announced the closing of a debt financing facility for up to $50 million provided by Rand Capital and Callodine Group.
2025-05-14	Date of the report.

Keywords

DarioHealth, digital therapeutics, revenue, financial results, Q1 2025, partnerships, debt refinancing, B2B2C, cardiometabolic, GLP-1, digital health

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.